FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 2) [2019] FCA 2215
File numbers: NSD 121 of 2012
NSD 837 of 2015Judge: YATES J Date of judgment: 11 September 2019 Catchwords: EVIDENCE – legal professional privilege - whether waiver privilege waived in certain communications Cases cited: Apotex Pty Ltd v Les Laboratoires Servier [2008] FCA 1466
Council of the New South Wales Bar Association v Archer (2008) 72 NSWLR 236
Ferella & Anor v Official Trustee in Bankruptcy (2010) 188 FCR 68
Macquarie Bank Limited v Arup Pty Limited [2016] FCAFC 117
Mann v Carnell (1999) 201 CLR 1
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8
Date of hearing: 11 September 2019 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 28 Counsel for the Applicants/Appellants: Mr S M Nixon SC and Mr J J Hutton Solicitor for the Applicants/Appellants: Jones Day Counsel for the Respondents: Mr S Habib SC and Mr A R Lang Solicitor for the Respondents: Wrays Lawyers ORDERS
NSD 121 of 2012
BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
Respondent
COMMONWEALTH OF AUSTRALIA
Other
JUDGE:
YATES J
DATE OF ORDER:
11 SEPTEMBER 2019
THE COURT ORDERS THAT:
1.The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
ORDERS
NSD 837 of 2015 BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
First Respondent
COMMONWEALTH OF AUSTRALIA
Other
JUDGE:
YATES J
DATE OF ORDER:
11 SEPTEMBER 2019
THE COURT ORDERS THAT:
1.The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
YATES J:
INTRODUCTION
Discovery was given by Otsuka Pharmaceutical Co., Ltd (Otsuka) and Bristol-Myers Squibb Company (BMS) (together, Otsuka/BMS) in relation to applications by them to amend two pleadings styled, in each case, Response to Statement of Particulars of Claim for Damages. The context in which the pleadings were filed is explained in Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230 and Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222. In essence, Otsuka/BMS had obtained an interim injunction…
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] FCA 2215
- Decision Date
CaseChat Overview and Summary
The legal issues that the court had to decide involved the nature and scope of legal professional privilege, and whether the privilege was waived by the nature and content of the communications revealed in the affidavits. Specifically, the court had to determine if the privilege was waived when certain communications were disclosed to Generic Health Pty Ltd for inspection. The affidavits provided details that suggested the communications contained legal advice on the basis for the admissions, which in turn revealed the substance of the communications.
The court found that the disclosures in Mr Kerr’s affidavit were sufficient to hold that any legal professional privilege which attached to the communications in the discovered documents had been waived. The court concluded that the privilege was waived by the nature of the communications revealed, which included legal advice and the basis on which the admissions were intended to be given. As such, the court ruled that the documents should be produced to Generic Health Pty Ltd for inspection.
ORDERS:
1. The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.
Orders
Orders of the court
1. The documents discovered by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company pursuant to orders made on 5 September 2019 be produced to Generic Health Pty Ltd for inspection.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi